Effect of sildenafil on skeletal and cardiac muscle in Becker muscular dystrophy

Annals of Neurology

Volumn 76, Issue 4, 2014, Pages 550-557

  Witting, Nanna ^a   Kruuse, Christina ^b   Nyhuus, Bo ^c   Prahm, Kira P ^a   Citirak, Gulsenay ^a   Lundgaard, Stine J ^d   Von Huth, Sebastian ^c   Vejlstrup, Niels ^c   Lindberg, Ulrich ^d   Krag, Thomas O ^a   Vissing, John ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c Rigshospitalet   (Denmark)

^d GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

NEURONAL NITRIC OXIDE SYNTHASE; NOS1 PROTEIN, HUMAN; PHOSPHODIESTERASE V; PIPERAZINE DERIVATIVE; PURINE DERIVATIVE; SILDENAFIL; SULFONE; VASODILATOR AGENT;

ADULT; ANALYSIS OF VARIANCE; BLOOD FLOW; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; FEMALE; FOLLOW UP; HAND STRENGTH; HEART MUSCLE; HUMAN; LOCOMOTION; MALE; METABOLISM; MUSCULAR DYSTROPHY, DUCHENNE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; SKELETAL MUSCLE; YOUNG ADULT;

ADULT; ANALYSIS OF VARIANCE; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HAND STRENGTH; HUMANS; LOCOMOTION; MAGNETIC RESONANCE IMAGING; MALE; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; MYOCARDIUM; NITRIC OXIDE SYNTHASE TYPE I; PIPERAZINES; PURINES; REGIONAL BLOOD FLOW; SULFONES; VASODILATOR AGENTS; YOUNG ADULT;

EID: 84907877519     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24216     Document Type: Article

References (27)

1. Yazaki M, Yoshida K, Nakamura A, et al. Clinical characteristics of aged Becker muscular dystrophy patients with onset after 30 years. Eur Neurol 1999;42:145-149.
2. Anthony K, Cirak S, Torelli S, et al. Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials. Brain 2011;134:3547-3559.
3. Magri F, Govoni A, D'Angelo MG, et al. Genotype and phenotype characterization in a large dystrophinopathic cohort with extended follow-up. J Neurol 2011;258:1610-1623.
4. Witting N, Duno M, Vissing J. Deletion of exon 26 of the dystrophin gene is associated with a mild Becker muscular dystrophy phenotype. Acta Myol 2011;30:182-184.
5. Chang WJ, Iannaccone ST, Lau KS, et al. Neuronal nitric oxide synthase and dystrophin-deficient muscular dystrophy. Proc Natl Acad Sci U S A 1996;93:9142-9147.
6. Brenman JE, Chao DS, Xia H, et al. Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy. Cell 1995;82:743-752.
7. Thomas GD, Sander M, Lau KS, et al. Impaired metabolic modulation of alpha-adrenergic vasoconstriction in dystrophin-deficient skeletal muscle. Proc Natl Acad Sci U S A 1998;95:15090-15095.
8. Thomas GD. Functional muscle ischemia in Duchenne and Becker muscular dystrophy. Front Physiol 2013;4:381.
9. Sander M, Chavoshan B, Harris SA, et al. Functional muscle ischemia in neuronal nitric oxide synthase-deficient skeletal muscle of children with Duchenne muscular dystrophy. Proc Natl Acad Sci U S A 2000;97:13818-13823.
10. Kobayashi YM, Rader EP, Crawford RW, et al. Sarcolemma-localized nNOS is required to maintain activity after mild exercise. Nature 2008;456:511-515.
11. Asai A, Sahani N, Kaneki M, et al. Primary role of functional ischemia, quantitative evidence for the two-hit mechanism, and phosphodiesterase-5 inhibitor therapy in mouse muscular dystrophy. PLoS One 2007;2:e806.
12. Lau KS, Grange RW, Chang WJ, et al. Skeletal muscle contractions stimulate cGMP formation and attenuate vascular smooth muscle myosin phosphorylation via nitric oxide. FEBS Lett 1998;431:71-74.
13. Sato K, Yokota T, Ichioka S, et al. Vasodilation of intramuscular arterioles under shear stress in dystrophin-deficient skeletal muscle is impaired through decreased nNOS expression. Acta Myol 2008;27:30-36.
14. Martin EA, Barresi R, Byrne BJ, et al. Tadalafil alleviates muscle ischemia in patients with Becker muscular dystrophy. Sci Transl Med 2012;4:162ra155.
15. Khairallah M, Khairallah RJ, Young ME, et al. Sildenafil and cardiomyocyte-specific cGMP signaling prevent cardiomyopathic changes associated with dystrophin deficiency. Proc Natl Acad Sci U S A 2008;105:7028-7033.
16. Adamo CM, Dai DF, Percival JM, et al. Sildenafil reverses cardiac dysfunction in the mdx mouse model of Duchenne muscular dystrophy. Proc Natl Acad Sci U S A 2010;107:19079-19083.
17. Percival JM, Whitehead NP, Adams ME, et al. Sildenafil reduces respiratory muscle weakness and fibrosis in the mdx mouse model of Duchenne muscular dystrophy. J Pathol 2012;228:77-87.
18. Chao DS, Gorospe JR, Brenman JE, et al. Selective loss of sarcolemmal nitric oxide synthase in Becker muscular dystrophy. J Exp Med 1996;184:609-618.
19. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148-2157.
20. 0#.ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111-117.
21. Vissing SF, Scherrer U, Victor RG. Stimulation of skin sympathetic nerve discharge by central command. Differential control of sympathetic outflow to skin and skeletal muscle during static exercise. Circ Res 1991;69:228-238.
22. Jensen TD, Kazemi-Esfarjani P, Skomorowska E, et al. A forearm exercise screening test for mitochondrial myopathy. Neurology 2002;58:1533-1538.
23. Gentil C, Leturcq F, Ben YR, et al. Variable phenotype of del45-55 Becker patients correlated with nNOSmu mislocalization and RYR1 hypernitrosylation. Hum Mol Genet 2012;21:3449-3460.
24. Lai Y, Thomas GD, Yue Y, et al. Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. J Clin Invest 2009;119:624-635.
25. Lai Y, Zhao J, Yue Y, et al. a2 and a3 helices of dystrophin R16 and R17 frame a microdomain in the a1 helix of dystrophin R17 for neuronal NOS binding. Proc Natl Acad Sci U S A 2013;110:525-530.
26. Bloom TJ. Cyclic nucleotide phosphodiesterase isozymes expressed in mouse skeletal muscle. Can J Physiol Pharmacol 2002;80:1132-1135.
27. Jendzjowsky NG, DeLorey DS. Role of neuronal nitric oxide in the inhibition of sympathetic vasoconstriction in resting and contracting skeletal muscle of healthy rats. J Appl Physiol (1985) 2013;115:97-106.